+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 270 Pages
  • November 2022
  • Region: Global
  • Roots Analysis
  • ID: 4575959

Bioavailability is known to form an integral part of the drug pharmacokinetics. As a result, over the last couple of years, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. Further, a study conducted on terminated drug development projects revealed that majority of the candidates fail in early phases. The study further highlighted that the aforementioned drug failures can primarily be attributed to the problems associated with pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related concerns. At present, more than 40% of the marketed drugs are believed to possess low bioavailability, while around 90% of all New Chemical Entities (NCEs), which are being evaluated in pre-clinical and clinical stages of development, exhibit solubility / permeability related issues. Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates. In fact, an increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability. 

In this context, it is also important to mention that a significant number of players engaged in the development of therapeutic interventions currently prefer to outsource their bioavailability enhancement operations to contract service providers. This trend can be attributed to the fact that service providers usually have specialized facilities and equipment, along with established processes, which can help drug developers to accomplish the desired goals in shorter timelines. In order to cater to the requirement for such services, a number of bioavailability enhancement focused service providers for API have been established in the past few years, across various regions of the globe. At present, the bioavailability enhancement service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. In fact, since 2017, close to 6,000 research articles, evaluating various bioavailability enhancement techniques have been published across several reputed journals. In addition, close to 10,000 patents have been filed, till 2022, providing a significant scientific push for the development of novel approaches. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is expected to grow at a steady pace in the foreseen future. 

Scope of the Report

The “Bioavailability Enhancement Technologies and Services Market (2nd Edition) by Drug Class (New Drug Approvals and Generics), BCS Classification (BCS II Drugs and BCS IV Drugs), Bioavailability Enhancement Approach (Solid Dispersion, Size Reduction, Lipid-based, and Other Approaches), Dosage Form (Liquids, Solids, Semi-Solids, and Fine Particles) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the bioavailability enhancement technologies and services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services. Amongst other elements, the report features:

  • An executive summary of the insights captured in our research. It offers a high-level view on the current state of bioavailability enhancement technologies and services market and its likely evolution in the mid-long term.
  • A general introduction to bioavailability enhancement, featuring information on the historical overview of bioavailability, assessment of drug bioavailability, need for bioavailability enhancement, and general factors affecting drug bioavailability. Additionally, the chapter includes details on the various types of bioavailability enhancement approaches / technologies employed by various industry stakeholders. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.
  • A detailed assessment of the overall market landscape of bioavailability enhancement service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / mirconization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, liquids, fine particles and semi-solids), and route of administration of drug product (oral, topical, parenteral and others).
  • A detailed assessment of the current market landscape of bioavailability enhancement technology providers, featuring analysis based on several parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various bioavailability enhancement technologies based on bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release, and others), bioavailability enhancement approach employed (solid dispersion, nanotechnology, lipid-based, other size reduction, chemical modification, and others), type of molecule (small molecules and biologics), type of dosage form supported (solids, liquids, fine particles, and semi-solids), route of administration (oral, topical, parenteral, and others), availability for license and associated intellectual property rights.
  • An in-depth analysis, highlighting the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as [F] a 3D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).
  • Elaborate profiles of various prominent players that are engaged in offering bioavailability enhancement technologies and services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), bioavailability enhancement services portfolio, recent developments and an informed future outlook.
  • A company benchmarking analysis of various players engaged in this domain. It highlights the capabilities of industry players in terms of their expertise across various services related to bioavailability enhancement of drug compounds and / or drug candidates. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry. 
  • An analysis of partnerships that have been inked between several stakeholders engaged in providing bioavailability enhancement services and technologies, during the period 2013-2022, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.
  • A detailed review of more than 5,800 peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on top journals, top publishers and top copyright holders (in terms of number of articles published)
  • An in-depth analysis of the patents that have been filed / granted for bioavailability enhancement approaches and technologies since 2003, based on important parameters, such as type of patent, patent application year, patent publication year, bioavailability enhancement approach, CPC symbols, geography, emerging focus area, type of organization, leading industry and non-industry players (in terms of number of patents filled / granted), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis.
  • An in-depth analysis of completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates, based on several relevant parameters, such as trial registration year, trial phase, current recruitment status, enrolled patient population, study design, type of sponsor / collaborator, leading industry and non-industry players (in terms of number of registered trials conducted), type of molecule and key geographies.
  • An elaborate analysis in order to estimate the current and future demand for bioavailability enhancement technologies and services, based on several relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs) and dosage form (liquids, solids, semi-solids, and fine particles / powders) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of New Chemical Entity (NCE) candidates and generic / reformulated drug products that are likely to undergo formulation development over the period of next 13 years.
  • A detailed market forecast analysis, highlighting the likely evolution of the bioavailability enhancement services market in the short to mid-term and long term, over the period 2022-2035. Further, the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs), bioavailability enhancement approach (solid dispersion, size reduction, and lipid-based), dosage form (liquids, solids, semi-solids, an fine particles / powders) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth. 
  • An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

  • Who are the key players engaged in the bioavailability enhancement technologies and services market?
  • Which are the key geographies where bioavailability enhancement technology and service providers are located?
  • What are the recent developments and expected trends in the bioavailability enhancement industry?
  • Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?
  • What is the evolving trend of publications focused on bioavailability enhancement technologies?
  • Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?
  • What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement technologies and services market?
  • How is the current and future opportunity likely to be distributed across key market segment?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Overview of Bioavailability
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability and Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.2. Studies in Healthy Subjects and Patients
3.3.2.1. Different Bioavailability Assessment methods
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
3.5.1. Drug Related Factors
3.5.2. Patient Physiology Related Factors
3.6. Bioavailability Enhancement Technologies
3.6.1. Physical Technologies for Bioavailability Enhancement
3.6.1.1. Solid Dispersion
3.6.1.1.1. Classification of Solid Dispersion Approaches
3.6.1.1.2. Methodologies for Solid Dispersion Approaches
3.6.1.1.2.1. Hot Melt Extrusion
3.6.1.1.2.2. Melting / Fusion Methods
3.6.1.1.2.3. Solvent Evaporation
3.6.1.1.2.4. Spray-Dried Dispersion
3.6.1.1.2.5. Other Techniques Used for Solid Dispersion
3.6.1.2. Nanosuspension Technology
3.6.1.2.1. Top-Down Approach
3.6.1.2.2. Bottom-Up Approach
3.6.1.3. Chemical Technologies for Bioavailability Enhancement
3.6.1.3.1. Lipid-Based Formulations
3.6.1.3.2. Non-Metal-Based Drug Delivery Systems
3.6.1.3.3. Polymer-Based Drug Delivery Systems
3.6.1.4. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle
4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1. Analysis by Solid Dispersion Approaches
4.2.5.2. Analysis by Size Reduction Approaches
4.2.5.3. Analysis by Lipid-Based Approaches
4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Financial Overview
7.2.3. Bioavailability Enhancement Services Portfolio
7.2.4. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
7.3.1. Company Overview
7.3.2. Financial Overview
7.3.3. Bioavailability Enhancement Services Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. Catalent
7.4.1. Company Overview
7.4.2. Financial Overview
7.4.3. Bioavailability Enhancement Services Portfolio
7.4.4. Recent Developments and Future Outlook
7.5. Formulex Pharma Innovations (formerly SoluBest)
7.5.1. Company Overview
7.5.2. Financial Overview
7.5.3. Bioavailability Enhancement Services Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Lonza
7.6.1. Company Overview
7.6.2. Financial Overview
7.6.3. Bioavailability Enhancement Services Portfolio
7.6.4. Recent Developments and Future Outlook
7.7. Lubrizol Life Science Health
7.7.1. Company Overview
7.7.2. Financial Overview
7.7.3. Bioavailability Enhancement Services Portfolio
7.7.4. Recent Developments and Future Outlook
7.8. Pace Analytical
7.8.1. Company Overview
7.8.2. Financial Overview
7.8.3. Bioavailability Enhancement Services Portfolio
7.8.4. Recent Developments and Future Outlook
7.9. Quotient Sciences
7.9.1. Company Overview
7.9.2. Financial Overview
7.9.3. Bioavailability Enhancement Services Portfolio
7.9.4. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
7.10.1. Company Overview
7.10.2. Financial Overview
7.10.3. Bioavailability Enhancement Services Portfolio
7.10.4. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Type of Bioavailability Enhancement Approach
10.3.4. Analysis by Year of Publication and Type of Bioavailability Enhancement Approach
10.3.5. Most Popular Journals: Analysis by Number of Publications
10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
10.3.7. Most Popular Publishers: Analysis by Number of Publications
10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
11.3.1. Analysis by Application Year
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Bioavailability Enhancement Approach
11.3.4. Analysis by CPC Symbols
11.3.5. Analysis by Geography
11.3.6. Analysis by Emerging Focus Areas
11.3.7. Analysis by Type of Organization
11.3.8. Leading Players: Analysis by Number of Patents
11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
12.3.1. Research Methodology
12.3.2. Analysis of Trials by Trial Registration Year
12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.4. Analysis of Trials by Study Design
12.3.5. Analysis of Trials by Trial Phase
12.3.6. Analysis of Trials by Trial Recruitment Status
12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
12.3.8. Analysis by Type of Molecule and Trial Phase
12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Study Focus
12.3.12. Analysis of Trials by Geography
12.3.13. Analysis of Enrolled Patient Population by Geography

13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
13.4. Analysis by Drug Class, 2022 and 2035
13.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
13.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035
13.5. Analysis by BCS Classification, 2022 and 2035
13.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035
13.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035
13.6. Analysis by Dosage, 2022 and 2035
13.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035
13.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035
13.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035
13.6.4. Demand for Bioavailability Enhancement Technologies and Services for FineParticles / Powders, 2022-2035
13.6.5. Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, 2022-2035
13.7. Concluding Remarks

14. MARKET FORECAST AND OPPURTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Bioavailability Enhancement Services Market, 2022-2035
14.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
14.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035
14.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035
14.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
14.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
14.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035
14.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
14.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches,2022-2035
14.6.2. Bioavailability Enhancement Services Market for Size Reduction Based Approaches, 2022-2035
14.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, 2022-2035
14.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, 2022-2035
14.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
14.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
14.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
14.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
14.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders,2022-2035
14.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035
14.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
14.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
14.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
14.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
14.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
14.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa,2022-2035
14.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
14.9. Concluding Remarks

15. TECHNOLOGY EVALUATION FRAMEWORK
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Technologies based on Solid Dispersion Approaches
15.3.1 List of Approved Drugs
15.3.2 Trends in Intellectual Capital
15.3.3. Trends in Research Activity
15.3.4. Business Model Adopted by Developers
15.4. Technologies based on Size Reduction Approaches
15.4.1 List of Approved Drugs
15.4.2 Trends in Intellectual Property
15.4.3. Trends in Research Activity
15.3.4. Business Model Adopted by Developers
15.5. Technologies based on Lipid-based Approaches
15.5.1 List of Approved Drugs
15.5.2 Trends in Intellectual Property
15.5.3. Trends in Research Activity
15.3.4. Business Model Adopted by Developers
15.6. Technology Evaluation Framework: Wind Rose Representation
15.7. Technology Evaluation Framework: Spider Web Representation
15.8. Results and Discussions

16. CONCLUSION17. APPENDIX I: LIST OF COMPANIES18. APPENDIX II: TABULATED DATA
List of Figures
Figure 2.1 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Clinical Trial Analysis
Figure 2.7 Executive Summary: Demand Analysis
Figure 2.8 Executive Summary: Market Forecast
Figure 3.1 Bioavailability Enhancement Technologies: Historical Evolution of Bioavailability Enhancement Technologies
Figure 3.2 Single Dose Study: Drug Concentration-Time Curve
Figure 3.3 Multiple Dose Study: Drug Concentration-Time Curve
Figure 3.4 Different Bioavailability Assessment Methods
Figure 3.5 Biopharmaceutical Classification System
Figure 3.6 Factors Affecting Drug Bioavailability
Figure 3.7 Solid Dispersion Formulations: Classification
Figure 3.8 Solid Dispersion Formulations: Preparation Methodologies
Figure 3.9 Solid Dispersion Formulations: Melt Agglomeration Technique
Figure 3.10 Nanosuspension Formulations: Preparation Methodologies
Figure 3.11 Lipid-based Formulations: Classification
Figure 3.12 Biological Formulations: Classification
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 4.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 4.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 5.1 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Figure 5.2 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Figure 5.3 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Leading Players: Distribution by Number of Technologies
Figure 5.7 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Figure 5.8 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Figure 5.9 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 5.10 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Figure 5.11 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Figure 5.12 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Figure 5.13 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Figure 5.14 Bioavailability Enhancement Technologies: Distribution by Availability for License
Figure 5.15 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Figure 6.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 6.2 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Figure 6.3 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Figure 6.4 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Figure 6.5 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 6.6 Key Insights: Distribution by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region
Figure 7.1 Adare Pharma Solutions: Bioavailability Enhancement Services Portfolio
Figure 7.2 Ascendia Pharmaceuticals: Bioavailability Enhancement Services Portfolio
Figure 7.3 Catalent: Annual Revenues, 2017-2022 (USD Billion)
Figure 7.4 Catalent: Bioavailability Enhancement Services Portfolio
Figure 7.5 Formulex Pharma Innovations (formerly SoluBest): Bioavailability Enhancement Services Portfolio
Figure 7.6 Lonza: Annual Revenues, 2017-2022 (H1) (CHF Billion)
Figure 7.7 Lonza: Bioavailability Enhancement Services Portfolio
Figure 7.8 Lubrizol Life Science Health: Bioavailability Enhancement Services Portfolio
Figure 7.9 Pace Analytical: Bioavailability Enhancement Services Portfolio
Figure 7.10 Quotient Sciences: Bioavailability Enhancement Services Portfolio
Figure 7.11 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, 2017-2022 (H1) (USD Billion)
Figure 7.12 WuXi STA (A Subsidiary of WuXi AppTec): Bioavailability Enhancement Services Portfolio
Figure 8.1 Company Benchmarking Analysis: Distribution by Year of Establishment and Location of Headquarters
Figure 8.2 Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
Figure 8.3 Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
Figure 8.4 Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
Figure 8.5 Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
Figure 8.6 Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
Figure 8.7 Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
Figure 8.8 Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
Figure 8.9 Benchmarking of Players based in Asia and Rest of the World, Established Post-2000 (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Figure 9.8 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Partner Headquarters
Figure 10.1 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Figure 10.4 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Figure 10.5 Most Popular Journals: Distribution by Number of Publications
Figure 10.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.7 Most Popular Publishers: Distribution by Number of Publications
Figure 10.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.9 Publication Analysis: Distribution by Popular Keywords
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Figure 11.3 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Figure 11.4 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, Pre-2010 - 2022
Figure 11.5 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Figure 11.6 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Figure 11.7 Patent Analysis: Distribution by CPC Symbols
Figure 11.8 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 11.9 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 11.10 Patent Analysis: Distribution by Emerging Focus Area
Figure 11.11 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Figure 11.12 Leading Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.14 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.15 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 11.16 Patent Analysis: Distribution of Patents by Age (Pre-2010 - 2022)
Figure 11.17 Bioavailability Enhancement: Patent Valuation
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2022
Figure 12.3 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.4 Bioavailability Studies: Distribution of Trials by Study Design
Figure 12.5 Bioavailability Studies: Distribution of Trials by Trial Phase
Figure 12.6 Bioavailability Studies: Distribution of Trials by Recruitment Status
Figure 12.7 Bioavailability Studies: Distribution of Trials by Type of Sponsor / Collaborator
Figure 12.8 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Figure 12.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.11 Bioavailability Studies: Distribution by Study Focus
Figure 12.12 Bioavailability Studies: Geographical Distribution of Trials
Figure 12.13 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Figure 13.1 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Figure 13.2 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035
Figure 13.3 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 (In Terms of Number of Projects)
Figure 13.4 Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 (In Terms of Number of Projects)
Figure 13.5 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035
Figure 13.6 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 13.7 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 13.8 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035
Figure 13.9 Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 (In Terms of Number of Projects)
Figure 13.10 Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 (In Terms of Number of Projects)
Figure 13.11 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 (In Terms of Number of Projects)
Figure 13.12 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 (In Terms of Number of Projects)
Figure 13.13 Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, 2022-2035 (In Terms of Number of Projects)
Figure 14.1 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Billion)
Figure 14.2 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035
Figure 14.3 Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035 (USD Billion)
Figure 14.4 Bioavailability Enhancement Services Market for Generics, 2022-2035 (USD Billion)
Figure 14.5 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035
Figure 14.6 Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035 (USD Billion)
Figure 14.7 Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035 (USD Billion)
Figure 14.8 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035
Figure 14.9 Bioavailability Enhancement Services Market for Lipid Based Approaches, 2022-2035 (USD Billion)
Figure 14.10 Bioavailability Enhancement Services Market for Size Reduction Based Approaches, 2022-2035 (USD Billion)
Figure 14.11 Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, 2022-2035 (USD Billion)
Figure 14.12 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, 2022-2035 (USD Billion)
Figure 14.13 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035
Figure 14.14 Bioavailability Enhancement Services Market for Liquids, 2022-2035 (USD Billion)
Figure 14.15 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Billion)
Figure 14.16 Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035 (USD Billion)
Figure 14.17 Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035 (USD Billion)
Figure 14.18 Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035 (USD Billion)
Figure 14.19 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035
Figure 14.20 Bioavailability Enhancement Services Market in North America, 2022-2035 (USD Billion)
Figure 14.21 Bioavailability Enhancement Services Market in Europe, 2022-2035 (USD Billion)
Figure 14.22 Bioavailability Enhancement Services Market in Asia, 2022-2035 (USD Billion)
Figure 14.23 Bioavailability Enhancement Services Market in Latin America, 2022-2035 (USD Billion)
Figure 14.24 Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 14.25 Bioavailability Enhancement Services Market in Rest of the World, 2022-2035 (USD Billion)
Figure 14.26 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Figure 15.1 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital
Figure 15.2 Technologies based on Solid Dispersion Approaches: Trends in Research Activity
Figure 15.3 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital
Figure 15.4 Technologies based on Size Reduction Approaches: Trends in Research Activity
Figure 15.5 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital
Figure 15.6 Technologies based on Lipid-based Approaches: Trends in Research Activity
Figure 15.7 Technology Evaluation Framework: Value Addition Matrix
Figure 15.8 Technology Evaluation Matrix
Figure 16.1 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 16.2 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 16.3 Concluding Remarks: Partnerships and Collaborations
Figure 16.4 Concluding Remarks: Publication Analysis
Figure 16.5 Concluding Remarks: Patent Analysis
Figure 16.6 Concluding Remarks: Clinical Trial Analysis
Figure 16.7 Concluding Remarks: Demand Analysis
Figure 16.8 Concluding Remarks: Market Forecast

List of Tables
Table 4.1 List of Bioavailability Enhancement Service Providers
Table 4.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle
Table 4.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach
Table 4.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches
Table 4.7 Bioavailability Enhancement Service Providers: Information on Other Bioavailability Enhancement Approaches
Table 4.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
Table 4.9 Bioavailability Enhancement Service Providers: Information on Routes of Administration
Table 5.1 List of Bioavailability Enhancement Technology Providers
Table 5.2 Bioavailability Enhancement Technologies: Information on Bioavailability Enhancement Principles and Bioavailability Enhancement Approaches
Table 5.3 Bioavailability Enhancement Technologies: Information on Type of Molecule
Table 5.4 Bioavailability Enhancement Technologies: Information on Dosage Forms
Table 5.5 Bioavailability Enhancement Technologies: Information on Routes of Administration
Table 5.6 Bioavailability Enhancement Technologies: Information on Availability for License and Intellectual Property Rights
Table 7.1 Adare Pharma Solutions: Company Snapshot
Table 7.2 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 7.3 Ascendia Pharmaceuticals: Company Snapshot
Table 7.4 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 7.5 Catalent: Company Snapshot
Table 7.6 Catalent: Recent Developments and Future Outlook
Table 7.7 Formulex Pharma Innovations (formerly SoluBest): Company Snapshot
Table 7.8 Formulex Pharma Innovations (formerly SoluBest): Recent Developments and Future Outlook
Table 7.9 Lonza: Company Snapshot
Table 7.10 Lonza: Recent Developments and Future Outlook
Table 7.11 Lubrizol Life Science Health: Company Snapshot
Table 7.12 Lubrizol Life Science Health: Recent Developments and Future Outlook
Table 7.13 Pace Analytical: Company Snapshot
Table 7.14 Pace Analytical: Recent Developments and Future Outlook
Table 7.15 Quotient Sciences: Company Snapshot
Table 7.16 Quotient Sciences: Recent Developments and Future Outlook
Table 7.17 WuXi STA (A Subsidiary of WuXi AppTec): Company Snapshot
Table 7.18 WuXi STA (A Subsidiary of WuXi AppTec): Recent Developments and Future Outlook
Table 9.1 Bioavailability Enhancement: List of Partnerships and Collaborations, 2013-2022
Table 9.2 Bioavailability Enhancement Focused Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 12.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 15.1 Technologies based on Solid Dispersion Approaches: List of Approved Drugs
Table 15.2 Technologies based on Size Reduction Approaches: List of Approved Drugs
Table 15.3 Technologies based on Lipid-based Approaches: List of Approved Drugs
Table 18.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 18.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 18.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Table 18.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 18.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 18.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Table 18.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 18.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 18.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Table 18.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 18.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 18.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Table 18.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Table 18.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 18.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Table 18.18 Leading Players: Distribution by Number of Technologies
Table 18.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Table 18.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Table 18.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Table 18.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Table 18.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Table 18.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Table 18.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
Table 18.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Table 18.28 Key Insights: Distribution by Company Size and Location of Headquarters
Table 18.29 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Table 18.30 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Table 18.31 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Table 18.32 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.33 Catalent: Annual Revenues, 2017-2022 (USD Billion)
Table 18.34 Lonza: Annual Revenues, 2017-2022 (H1) (CHF Billion)
Table 18.35 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, 2017-2022 (H1) (USD Billion)
Table 18.36 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Table 18.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.41 Most Active Players: Distribution by Number of Partnerships
Table 18.42 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Table 18.43 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 18.44 Partnerships and Collaboration: Distribution by Type of Partnership and Location of Partner Headquarters
Table 18.45 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Table 18.46 Publication Analysis: Distribution by Type of Publication
Table 18.47 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.48 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Table 18.49 Most Popular Journals: Distribution by Number of Publications
Table 18.50 Most Popular Journals: Distribution by Journal Impact Factor
Table 18.51 Most Popular Publishers: Distribution by Number of Publications
Table 18.52 Most Popular Copyright Holders: Distribution by Number of Publications
Table 18.53 Patent Analysis: Distribution by Type of Patent
Table 18.54 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Table 18.55 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Table 18.56 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications and Number of Granted Patents, Pre-2010-2022
Table 18.57 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.58 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Table 18.59 Patent Analysis: Distribution by CPC Symbols
Table 18.60 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.61 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.62 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Table 18.63 Leading Industry Players: Distribution by Number of Patents
Table 18.64 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.65 Leading Patent Assignees: Distribution by Number of Patents
Table 18.66 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 18.67 Patent Analysis: Distribution of Patents by Age (pre-2010-2022)
Table 18.68 Bioavailability Enhancement: Patent Valuation
Table 18.69 Leading Patents: Distribution by Number of Citations
Table 18.70 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 18.71 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.72 Bioavailability Studies: Distribution of Trials by Study Design
Table 18.73 Bioavailability Studies: Distribution of Trials by Trial Phase
Table 18.74 Bioavailability Studies: Distribution of Trials by Recruitment Status
Table 18.75 Bioavailability Studies: Distribution of Trials by Type of Sponsor /Collaborator
Table 18.76 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Table 18.77 Leading Industry Players: Distribution by Number of Registered Trials
Table 18.78 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 18.79 Bioavailability Studies: Distribution by Study Focus
Table 18.80 Bioavailability Studies: Geographical Distribution of Trials
Table 18.81 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Table 18.82 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Table 18.83 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035
Table 18.84 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 (In Terms of Number of Projects)
Table 18.85 Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 (In Terms of Number of Projects)
Table 18.86 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035
Table 18.87 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 (In Terms of Number of Projects)
Table 18.88 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 (In Terms of Number of Projects)
Table 18.89 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035
Table 18.90 Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 (In Terms of Number of Projects)
Table 18.91 Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 (In Terms of Number of Projects)
Table 18.92 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 (In Terms of Number of Projects)
Table 18.93 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 (In Terms of Number of Projects)
Table 18.94 Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, 2022-2035 (In Terms of Number of Projects)
Table 18.95 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Billion)
Table 18.96 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035
Table 18.97 Bioavailability Enhancement Services Market for New Drug Approvals, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.98 Bioavailability Enhancement Services Market for Generics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.99 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035
Table 18.100 Bioavailability Enhancement Services Market for BCS II Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.101 Bioavailability Enhancement Services Market for BCS IV Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.102 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035
Table 18.103 Bioavailability Enhancement Services Market for Lipid Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.104 Bioavailability Enhancement Services Market for Size Reduction Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.105 Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.106 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.107 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035
Table 18.108 Bioavailability Enhancement Services Market for Liquids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.109 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Billion)
Table 18.110 Bioavailability Enhancement Services Market for Semi-Solids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.111 Bioavailability Enhancement Services Market for Fine Particles / Powders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.112 Bioavailability Enhancement Services Market for Other Dosage Forms, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.113 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035
Table 18.114 Bioavailability Enhancement Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.115 Bioavailability Enhancement Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.116 Bioavailability Enhancement Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.117 Bioavailability Enhancement Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.118 Bioavailability Enhancement Services Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.119 Bioavailability Enhancement Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.120 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Table 18.121 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital
Table 18.122 Technologies based on Solid Dispersion Approaches: Trends in Research Activity
Table 18.123 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital
Table 18.124 Technologies based on Size Reduction Approaches: Trends in Research Activity
Table 18.125 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital
Table 18.126 Technologies based on Lipid-based Approaches: Trends in Research Activity
Table 18.127 Technology Evaluation Framework: Value Addition Matrix
Table 18.128 Technology Evaluation Matrix

Executive Summary

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:


  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the bioavailability enhancement technologies and services market in the short-mid and long term.

Chapter 3 is a general introduction to bioavailability. In this section, we have discussed, in detail, the concept of bioavailability and the current problems associated with bioavailability across various drug compounds. The chapter also features a detailed discussion on the current approaches being used for bioavailability enhancement.

Chapter 4 provides a comprehensive review of the global landscape of bioavailability enhancement technologies and service providers. It includes information related to over 150 companies that are currently operating in this domain. It features an in-depth market review, including a study of the regional distribution of players, analysis by company size and year of establishment, approach adopted for bioavailability enhancement, type of drug dosage form, route of administration, and the location of the company.

Chapter 5 features detailed profiles of some of the key players that are active in this domain and offer a wide range of services. Each profile presents an overview of the company, its financial information (if available), details related to its service(s) portfolio, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 6 presents a benchmark analysis of all the players engaged in this domain. It highlights the capabilities of these companies in terms of their expertise across bioavailability enhancement. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.

Chapter 7 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this domain. In addition, we have highlighted the key players, on the basis of the number of collaborations and also discussed the expansion of services (via acquisitions / mergers) by key players.

Chapter 8 provides a comprehensive publication analysis, highlighting the recent trends in published literature related to bioavailability enhancement technologies. It presents a relative comparison of key technologies, on the basis of the trend in number of publications (CAGR) and the impact factors of the journals wherein these articles were published.

Chapter 9 provides detailed analysis of the patents that have recently been filed related to bioavailability enhancement technologies. The study also highlights the upcoming trends in innovation in this domain. In addition, it presents a high-level view on the valuation of these patents

Chapter 10 features an overview of the various ongoing clinical studies that are evaluating the bioavailability of various drug candidates that are currently under development. The chapter features a comprehensive view on the focus areas of these clinical studies, highlighting the key players involved as well.

Chapter 11 presents a detailed estimation of the likely demand for bioavailability enhancement technologies / services. It provides a comprehensive view in terms of the annual number of projects that are likely to require bioavailability enhancement in the period 2018-2030.

Chapter 12 provides a comprehensive market forecast analysis, highlighting the future potential of contract services for bioavailability enhancement till the year 2030. It features the likely distribution of the market based on [A] approach used for bioavailability enhancement (solid dispersion, size reduction, lipid-based approaches, and other approaches), [B] region (North America, Europe, Asia-Pacific and rest of the world), and [C] opportunity from drugs across different BCS classifications (BCS II and BCS IV).

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of this market in the foreseen future.

Chapter 14 is a collection of transcripts of the discussions by various stakeholders across the public domain.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Companies Mentioned

  • AbbVie Contract Manufacturing
  • ABITEC
  • Absorption Systems
  • Accu-Break Pharmaceuticals
  • Aché Laboratórios Farmacêuticos
  • Acorda Therapeutics
  • Actavis
  • Adare Pharma Solutions
  • Admas Pharmaceuticals
  • ADYA
  • Aegis Therapeutics
  • Aeon Respire
  • Aerami Therapeutics
  • Agere Pharmaceuticals
  • Agios Pharmaceuticals 
  • Aizant Drug Research Solutions
  • Ajinomoto Bio-Pharma Services
  • Alcami
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alimera Sciences
  • Alkermes
  • Allergan
  • Altasciences
  • Althea Technologies
  • Altus Drug Development
  • Amador Bioscience
  • Amatsigroup
  • AMRI
  • APONTIS PHARMA
  • Applied Manufacturing Science (AMS)
  • Aptuit
  • Aragen Life Sciences (Formerly GVK Bio)
  • Arbro Pharmaceuticals
  • Arcinova
  • Ardena
  • Ascendia Pharmaceuticals
  • Ascentage Pharma
  • Ash Stevens
  • Ashland
  • Astex Pharmaceuticals
  • Aurigene Discovery Technologies
  • Avista Pharma Solutions
  • Axsome Therapeutics
  • BASF
  • Bend Research
  • Betta Pharmaceuticals
  • BiGEN
  • Bio-Concept Laboratories
  • BioConnection
  • BioCorRx
  • BioDuro-Sundia
  • BioGeneration Ventures (BGV)
  • Biolingus
  • Bionpharma
  • Bioqube Ventures
  • Biosidus
  • BIOTTS
  • Bristol Myers Squibb
  • Calvert Laboratories
  • Cambrex
  • Camurus
  • Capsugel
  • Cara Therapeutics
  • Caraway Therapeutics
  • Catalent
  • CD Formulation
  • ChemConnection
  • CMC Pharmaceuticals
  • Co-Formulate
  • Colorcon
  • Comera LIFE SCIENCES
  • COREALIS Pharma
  • CoreRx
  • Coripharma
  • Creative Biolabs
  • CritiTech Particle Engineering Solutions
  • Crystal Pharmatech
  • Crystallics
  • CrystecPharma
  • Curia (Formerly AMRI)
  • CuriRx
  • Curis
  • Cyclolab
  • Dalton Pharma Services 
  • Dana Farber Cancer Institute
  • Dauntless Pharmaceuticals
  • DisperSol Technologies
  • Dizal Pharmaceutical
  • Dolomite Microfluidics
  • Drug Delivery Experts (Acquired by Pace Life Sciences)
  • DSM Nutritional Products
  • Eagle Pharmaceuticals
  • Element Materials Technology
  • Emmerson Resources
  • Ennaid Therapeutics
  • Enteris BioPharma
  • EPFL
  • Epigeneron
  • Equinox Science (Acquired by Betta Pharmaceuticals)
  • ESSA PHARMA
  • Eurofarma
  • Eurofins CDMO
  • Evonik Health Care
  • Evotec
  • ExCellThera
  • Excivion
  • Exelead
  • ExxPharma Therapeutics
  • EyePoint Pharmaceuticals
  • Federal Equipment
  • Ferring Pharmaceuticals
  • Flexion Therapeutics
  • Forbion
  • Forest Laboratories
  • Formac Pharmaceuticals
  • Formex
  • Formulex Pharma Innovations (Formerly SoluBest)
  • Foster Delivery Science
  • Frazier Healthcare Partners
  • Fudan University
  • Fuji Chemical Industries
  • Gattefossé
  • GB Sciences
  • Gen-Plus
  • Glatt
  • Glenmark Pharmaceuticals
  • GP Pharm
  • Halo Pharmaceutical (Acquired by Cambrex)
  • Harvard University
  • Hemmo Pharmaceuticals
  • Hofseth BioCare (HBC)
  • Honeywell
  • Hovione
  • Hubei Yuyang Pharmaceutical (Acquired by Proton)
  • IACTA Pharmaceuticals
  • iCeutica (Acquired by Iroko Pharmaceuticals)
  • Icon Bioscience (Acquired by pSivida)
  • Iconovo
  • Idifarma
  • Nutrition & Biosciences (A subsidiary of IFF)
  • I-Mab
  • Impact Therapeutics
  • Inflexion
  • InfraRed Integrated Systems (Irisys)
  • Inspira Pharmaceuticals
  • Instillo Group
  • Intas Pharmaceuticals
  • Interpublic (IPG)
  • iX Syrinx (A subsidiary of iX Biopharma)
  • Janssen Pharmaceutica
  • Jetpharma
  • Ji Xing Pharmaceuticals
  • Jina Pharmaceuticals
  • JLL Partners
  • Johns Hopkins University
  • J-Star Research
  • Juniper Pharmaceuticals
  • KC Pharmaceuticals (Acquired by Kangen Pharmaceuticals)
  • Kuecept
  • Kuraray
  • LakePharma
  • Larodan
  • LATITUDE Pharmaceuticals
  • Leonard Green & Partners
  • leon-nanodrugs
  • Lexaria Bioscience
  • Ligand Pharmaceuticals
  • Lipomize
  • Lonza
  • Losan Pharma
  • Lubrizol Life Science Health
  • LYOCONTRACT
  • Marinus Pharmaceuticals
  • Massachusetts Institute of Technology
  • Mayne Pharma
  • Merck Millipore
  • Merrion Pharmaceuticals
  • Metrics Contract Services
  • MGB Biopharma
  • Micro-Macinazione
  • Micro-Sphere
  • Midas Pharma
  • MIKA Pharma
  • Moderna
  • Monash University
  • MRM Health
  • Nanocopoeia
  • Nanomaterials
  • NanoMaterials Technology (NMT)
  • Nanomerics
  • Natco Pharma
  • Nemus Bioscience
  • NETZSCH Premier Technologies
  • NeutriSci International
  • New York Center for Nanomedicine Research
  • Nextar Chempharma Solutions
  • Nicox
  • NLS Pharmaceutics
  • Nordic Bioscience
  • Novan
  • Novo Nordisk
  • Nuance Pharma
  • Nuformix Technologies
  • OcuMension Therapeutics 
  • Okklo Life Sciences
  • Opiant Pharmaceuticals
  • Orbis Biosciences
  • Oryn Therapeutics
  • Oxilio
  • Pace Life Sciences
  • Pacira BioSciences
  • Particle Sciences
  • Patheon
  • PCI Pharma Services
  • Peak Proteins
  • Pensatech Pharma
  • Permira
  • Pfizer
  • Pharmaceutical Manufacturing Research Services (PMRS)
  • Pharmaceutical Product Development
  • Pharmaceutics International
  • Pharmaron
  • PharmaSol
  • Pharmatek
  • Pharmaterials
  • Pharmavize
  • Phasex
  • Phenom Pharmaceuticals (Acquired by Thermo Fisher Scientific)
  • Phosphorex
  • Piramal Pharma Solutions
  • PixarBio
  • Porton Pharma Solutions
  • PowderSize
  • ProJect Pharmaceutics
  • ProMed Pharma
  • PSC Biotech
  • Pulmatrix
  • QDevelopment 
  • QS Pharma
  • Quay Pharma (A subsidiary of SGS)
  • Quotient Sciences
  • RenaSci (Acquired by Sygnature Discovery)
  • Rhythm Pharmaceuticals
  • Rottendorf Pharma
  • Samyang Biopharmaceuticals
  • SARA Pharm Solutions
  • Scripps Research
  • SEPS Pharma
  • Serán Bioscience
  • Sever Pharma Solutions (Formerly Foster Delivery Science)
  • SGS
  • Sichuan University
  • Siegfried Holding
  • SignalRx Pharmaceuticals
  • Singota Solutions
  • Sino German M&A Service
  • SiTec PharmaBio
  • SkyePharma
  • SocietalTM CDMO (Formerly Recro)
  • Sofpromed
  • SolMic Research
  • Solvay
  • Solvias
  • SRAX
  • STA Pharmaceutical
  • Standard Industries
  • Stanipharm
  • Sundia
  • Supernus Pharmaceuticals
  • Sygnature Discovery
  • Syntagon
  • Tapemark
  • Temasek
  • Tergus Pharma
  • The University of Texas
  • Thermo Fisher Scientific
  • Thomas H Lee Partners
  • Univar
  • University of California
  • UPM Pharmaceuticals
  • Upperton Pharma Solutions
  • Vaccine Manufacturing Innovation Centre (VMIC)
  • Vectura
  • Vertex Pharmaceuticals
  • Vesifact
  • Virpax Pharmaceuticals
  • VxP Pharma
  • Water Street Healthcare Partners
  • Wolfe Laboratories
  • W. R. Grace
  • WuXi AppTec
  • Xcelience
  • Xedev
  • Yale University
  • Ypsomed
  • Zerion Pharma

Methodology

 

 

Loading
LOADING...